Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Feb 23 04:00PM ET
22.93
Dollar change
-0.03
Percentage change
-0.13
%
Index- P/E- EPS (ttm)-8.71 Insider Own41.61% Shs Outstand16.95M Perf Week2.23%
Market Cap388.66M Forward P/E- EPS next Y-3.42 Insider Trans0.00% Shs Float9.90M Perf Month2.41%
Income-30.50M PEG- EPS next Q-0.64 Inst Own75.96% Short Float5.53% Perf Quarter76.52%
Sales37.34M P/S10.41 EPS this Y89.77% Inst Trans-6.85% Short Ratio0.57 Perf Half Y178.95%
Book/sh1.11 P/B20.75 EPS next Y-63.74% ROA-46.54% Short Interest0.55M Perf Year186.63%
Cash/sh1.86 P/C12.30 EPS next 5Y- ROE-284.33% 52W Range3.11 - 22.96 Perf YTD101.67%
Dividend Est.- P/FCF- EPS past 5Y-24.57% ROI-189.78% 52W High-0.13% Beta2.10
Dividend TTM- Quick Ratio1.89 Sales past 5Y73.53% Gross Margin92.45% 52W Low637.30% ATR (14)0.35
Dividend Ex-Date- Current Ratio1.89 EPS Y/Y TTM59.57% Oper. Margin-100.14% RSI (14)82.10 Volatility0.67% 0.73%
Employees50 Debt/Eq3.19 Sales Y/Y TTM16.14% Profit Margin-81.68% Recom2.56 Target Price22.42
Option/ShortYes / Yes LT Debt/Eq2.54 EPS Q/Q87.04% Payout- Rel Volume1.73 Prev Close22.96
Sales Surprise2.94% EPS Surprise85.24% Sales Q/Q-67.33% EarningsNov 09 AMC Avg Volume955.92K Price22.93
SMA202.22% SMA5026.02% SMA200129.37% Trades Volume1,650,427 Change-0.13%
Date Action Analyst Rating Change Price Target Change
Jan-05-24Initiated Oppenheimer Outperform $23
Nov-20-23Initiated TD Cowen Outperform
Jul-06-22Resumed Canaccord Genuity Buy $16
Sep-28-21Upgrade Citigroup Neutral → Buy $16
Jun-08-21Downgrade Citigroup Buy → Neutral $25 → $16
Jun-07-21Downgrade Wedbush Outperform → Neutral
May-28-21Initiated Cantor Fitzgerald Overweight $40
May-10-21Initiated Piper Sandler Overweight $35
Dec-23-20Resumed H.C. Wainwright Buy $31
May-22-20Initiated Piper Sandler Overweight $35
Jan-25-24 08:03AM
Jan-23-24 02:45PM
08:45AM
Jan-19-24 01:15PM
Jan-10-24 03:07PM
07:48PM Loading…
Jan-08-24 07:48PM
04:43PM
04:23PM
03:39PM
01:30PM
01:13PM
12:19PM
11:30AM
09:19AM
08:06AM
08:00AM Loading…
08:00AM
07:30AM
07:30AM
12:33AM
Dec-26-23 07:30AM
Dec-19-23 07:30AM
Dec-11-23 08:15PM
09:55AM
Dec-08-23 04:06PM
Dec-05-23 12:00PM
Nov-30-23 11:07AM
09:55AM
Nov-15-23 08:50AM
Nov-14-23 09:55AM
Nov-09-23 04:01PM
09:15AM Loading…
Nov-02-23 09:15AM
Oct-23-23 07:17AM
Oct-21-23 11:31AM
Oct-16-23 04:05PM
Oct-09-23 04:17PM
Sep-28-23 03:00AM
Sep-15-23 07:15AM
Sep-13-23 04:05PM
Sep-06-23 07:30AM
Sep-05-23 08:05AM
08:00AM
Aug-09-23 05:40PM
04:01PM
Aug-03-23 07:30AM
Aug-01-23 07:30AM
Jul-10-23 09:00AM
Jun-27-23 07:30AM
Jun-26-23 05:14PM
May-28-23 08:24AM
May-11-23 05:55PM
04:30PM
May-09-23 05:25PM
Apr-18-23 01:30PM
Apr-17-23 01:30PM
Apr-10-23 04:05PM
Apr-01-23 08:40AM
Mar-29-23 06:24AM
Mar-27-23 04:05PM
04:02PM
Mar-14-23 06:21PM
Feb-08-23 07:50AM
Feb-07-23 07:30AM
Feb-02-23 11:28AM
Jan-25-23 08:50AM
Dec-16-22 12:09PM
Dec-12-22 07:37AM
Dec-11-22 10:00AM
Dec-05-22 07:30AM
Nov-21-22 04:59PM
Nov-19-22 07:12AM
Nov-14-22 05:25PM
04:01PM
Nov-03-22 09:09AM
Oct-04-22 07:30AM
Sep-19-22 04:05PM
Sep-01-22 07:30AM
Aug-17-22 06:07AM
Aug-10-22 05:15PM
04:01PM
07:32AM
Aug-02-22 07:30AM
Jul-26-22 07:19AM
Jul-06-22 07:30AM
Jun-27-22 12:50PM
04:15AM
May-26-22 05:00PM
May-14-22 08:20AM
May-12-22 05:25PM
04:05PM
May-04-22 04:06PM
May-02-22 09:00AM
Apr-18-22 10:56AM
Apr-12-22 07:30AM
Apr-07-22 04:05PM
07:30AM
Mar-11-22 10:53AM
Mar-10-22 05:45PM
04:04PM
Mar-08-22 06:55PM
Mar-07-22 07:30AM
Harpoon Therapeutics, Inc. is a clinical-stage immunotherapy company, which engages in the development of antibodies. It focuses on the research of novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases. The firm utilizes its proprietary Tri-specific T cell Activating Construct platform to create a pipeline of novel TriTACs for the treatment of solid tumors and hematologic malignancies. The company was founded by Patrick A. Baeuerle, Luke B. Evnin, and Jeanmarie Guenot on March 19, 2015 and is headquartered in South San Francisco, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
HUNT RONALDDirectorMar 23Buy1.0010,00010,00010,000Mar 27 05:37 PM